Objective: Disorders of Sex Development (DSD) is defined as a condition in which chromosomal sex is inconsistent with phenotypic sex, or in which the phenotype is not classifiable as either male or female.
Syndrome; USG = Ultrasonography; AMH = Anti=Mullarian Hormone; FSH = Follicle Stimulating Hormone.
Introduction:
The term disorder of sex development (DSD) includes congenital conditions in which development of chromosomal, gonadal or anatomical sex is atypical [1] . Leydig cell hypoplasia exemplifies a unique category of 46, XY DSD resulting from inability of LH-CGR in Leydig cell to respond to circulating LH thereby causing complete/incomplete feminization of a male fetus. The underlying gene defect in Leydig cell hypoplasia was first described by Kremer et al [2] and various other defects have since been described [3, 4, 5] . Patients are characterized by ambiguous or female external genitalia. Complete absence of virilization results in normal female external genitalia and they generally seek medical attention at pubertal age due to the absence of breast development and/or primary amenorrhoea.
Case presentation:
A 27-year-old apparently healthy looking unmarried female presented with the complaint of failure to establish spontaneous menstruation till date. She was the second issue of a consanguineous marriage. Her mother stated that she was born at term uneventfully by normal vaginal delivery and her antenatal period was unremarkable.
They noticed seemingly normal female external genitalia and she was reared as female. Her neonatal and childhood period was uneventful including attainment of developmental milestone. However, pubertal changes were somewhat delayed with adrenarche evident at the age of 14 years. She noticed acceleration of height in comparison to her peers at the age of 17 years. Her breast development was poor till date and menarche did not ensue. She gave no history suggestive of adrenal insufficiency. There was no family history of genital ambiguity, pubertal virilization or early infantile death. However one of her brothers has unilateral cryptorchidism. Her mother recalled that her elder sister had herniorraphy at 3 years of age with removal of ovoid structure from the hernial sac. At present this elder sister is married though infertile ( Fig: 1 ). Our patient had an ultrasonography (USG) of pelvis done few years back showing absence of uterus or ovaries. As remedy for primary amenorrhea she took medication probably norethisterone without any effect. (Table-1) . So, at this point CAIS was excluded and we revised our differentials into LH receptor resistance, Leydig cell hypoplasia or enzymatic defect in testosterone biosynthetic pathway.
For categorization of type of Leydig cell defect HCG stimulation test was performed. There was negligible increase in serum testosterone level which under normal circumstances would have been 2-20 folds higher (Table-2 ). Ancillary tests of adrenal functions were found to be normal that commonly are abnormal in enzymatic block of steroid synthesis (table-2). To confirm our diagnosis we planned further investigations like: C19/C21 steroids, Sequence analysis of LHCGR gene mutation and histopathology study following orchiectomy. MRI of the abdomen was done that showed rudimentary prostate at bladder base (Fig-2 ).Following these comprehensive work-up she underwent bilateral orchiectomy with vaginoplasty and the diagnosis was established by histopathology reports (Fig-3 ). For the genetic analysis of LHCGR gene, DNA was extracted from peripheral blood cells using QIAGEN blood DNA isolation kit and the exons were amplified with specific primers. PCR products were then purified and analyzed by capillary electrophoresis based on Sanger sequencing protocol. The DNA sequencing of the patient's LHCGR gene did not reveal any mutations in its coding sequences. To investigate the expression of LHCGR gene in peripheral blood monocyte, RNA was extracted from peripheral blood cells and reverse-transcribed to synthesize cDNA. cDNA of LHCGR genes was amplified using PCR with specific primers long with GAPDH as control. However it did not exclude the possibility of alteration in the introns, promotor region and other supporting genes rather than LH-CGR ( Fig-4) .
After orchiectomy and vaginal dilatation she was estrogenized. Her diagnosis and its impact on fertility was only disclosed to her. Recently she got married and is living a happy life. All her family members are undergoing genetic screening.
Discussion:
The term 'disorders of sex development' (DSD) is proposed to define congenital conditions in which a disharmony between chromosomal, gonadal and anatomical sex exists [6] . Human sex development is a highly complex process controlled by multiple genes and hormones. Sexual differentiation follows a sequence of events with sequential development of the gonads, internal genital ducts and the external genitalia [7] .
Abnormalities of sexual differentiation may occur at any step along the way producing predictable clinical syndromes. Many defects of sexual differentiation are evident at birth, others will not be identified until puberty, at which time the patient may manifest aberrant external maturation or may remain sexually infantile In 1976, Berthezene et al. described the first patients with LCH and subsequently other cases have been reported [7, 8] . Also known as Leydig cell agenesis, it is a rare autosomal recessive genetic and endocrine syndrome affecting an estimated 1 in 1,000,000 individuals. It is characterized by an inability of the body to respond to LH, which is normally responsible for signaling Leydig cells of the testicles to produce testosterone and other androgen sex hormones. It is caused by genetic mutations in LH-CGR, a gene which encodes the LH/hCG receptor [11] . The LHCGR gene is mapped to chromosome 2p21. The 674amino-acid protein is a seven-transmembrane domain G-protein-coupled receptor. LH normally acts through the LH/hCG receptor to stimulate the growth of Leydig cells in the testicles and the production of androgens such as testosterone and dihydrotestosterone. In utero, placental hCG stimulates Leydig cells to produce testosterone, resulting in male internal and external genitalia. LH takes over during the third trimester of gestation and neonatal life to complete Leydig cell development and continue testosterone production [13] . In LCH however, there is a reduced capacity for the LH/hCG receptor to respond to LH. This result in hypoplasia or absence of Leydig cells, testicular atrophy, and lower than normal androgen levels. LCH has been classified into two subtypes based on clinical severity, ranging from almost entirely female external genitalia appearance with undescended testes, namely disorders of sexual differentiation (DSD) (type 1), to a relatively mild phenotype of micropenis and/ or hypospadias and/or cryptorchidism (type 2) [13] . It is complete/incomplete resistance of the LH-CGR receptor that determines the phenotype. This is why certain individuals with this condition have more or less severe variations of this condition (for example, micropenis vs. female external genitalia).
The subject in our case report is a notable example of complete LCH. She was brought up as a typical female. At birth she was given a female sex assignment because of apparently normal appearing female external genitalia. Later at the age of 27 years, she presented to us with primary amenorrhea and hypogonadism. Her family history of consanguinity of marriage and herniorapphy in her elder sister pointed toward a genetic disorder. Our provisional diagnosis was Mullerian agenesis which however was changed because of presence of testes. Now she represented a case of 46XY DSD and as assumed her karotype was found to be so. USG of abdomen showed absence of Mullerian structures with Wolffian duct remnants and testes in inguino-valvar region. There was low testosterone levels despite elevated gonadotrophin levels and LH predominant over FSH levels. On hCG stimulation, testicular unresponsiveness with no abnormal step up in testosterone bisynthetic precursors was noted. Ultimately diagnosis was confirmed from orchiectomy followed by histopathology showing atrophic change with DOI:10.4158/ACCR-2019-0152 © 2019 AACE.
absent Leydig cell with relative preservation of Sertoli cell. However genetic analysis failed to reveal any mutation of the LH-CGR gene. Till now over 20 inactivating mutations of LHCGR have been identified, scattered throughout the gene (13, 14) . Even then there are handful of case report or series where none could have been identified. Richter-Unruh A1 et al. analysed ten patients with a clinical phenotype of LCH for mutations in the complete coding region of the LH receptor gene. Three mutations (33 bp insertion in exon 1; W491* and I625K) were identified that explained the phenotype in two patients. A compound heterozygous case of complete Leydig hypoplasia was found to have mutation on the paternal allele identified in codon 343 a T to A transversion that changes a conserved cysteine in the hinge region of the receptor to serine (C343S); on the maternal allele a T to C transition causes another conserved cysteine at codon 543 in trans-membrane segment 5 to be altered to arginine (C543R). Both of these mutant receptors are completely devoid of hormone-induced cAMP reporter gene activation. initial translocation to the endoplasmic reticulum of these mutant receptors is normal. After that, however, translocation is halted or misrouted, and as a result, neither mutant ever reaches the cell surface, and they cannot bind hormone. [14] Another case reported nonsense mutation (Cys545Stop) in the paternal human LH/CG receptor (hLHR) allele in a family with two 46,XY children afflicted with Leydig cell hypoplasia.
This mutation abolished the signal transduction capability of the affected hLHR.
[15] However, most of the patients with the clinical phenotype of LCH did not have causative mutations, suggesting that changes in other regions of the LH receptor gene, such as the large introns or the promoter region, may be responsible for the majority of cases. Alternatively, the displayed phenotype may be the result of other genetic defects. Theirs as well as others work further underscores the importance of thorough clinical analysis of patients before molecular analysis of a particular gene is performed [16] .At present our patient is on estrogen replacement therapy having undergone bilateral orchiectomy and vaginoplasty.
Conclusion:
Leydig cell hypoplasia represents a unique paradox of sex development that needs to be solved by a multidisciplinary team with an empathetic approach. Clinical, chromosomal and hormonal assessment may help in making the presumptive etiological diagnosis. Further molecular genetic analyses are useful in differentiating these abnormalities and to make a final diagnosis. Early detection, judicious gender assignment along with reconstructive genital surgery followed by hormonal therapy form the mainstay of treatment. 
